Healthcare Private Placement and M&A Transactions Review Week Ending June 9, 2024

ITM Isotope Technologies: The company received EUR 188 million of development capital from Temasek Holdings, Carbyne Equity Partners, Athos, BlackRock and Qatar Investment Authority on June 6, 2024. The company is an operator of a radiopharmaceutical biotech company intended to improve the treatment outcome of cancer patients.

Sword Health: The company raised $130 million of venture funding from Oxy Capital, Lince Capital and other undisclosed investors on June 4, 2024, putting the company’s pre-money valuation at $2.97 billion. The company is a developer of an artificial intelligence care platform designed to deliver customized care to patients globally.

Delfi Diagnostics: The company raised an additional estimated $100 million of Series B venture funding from Merck Global Health Innovation Fund and other undisclosed investors on June 3, 2024, putting the company’s pre-money valuation at $625 million. The company is a developer of a blood test system designed for the early detection of cancer.

Vilya: The company raised $71 million in Series A venture funding in a deal led by ARCH Venture Partners on June 4, 2024, putting the company’s pre-money valuation at $73 million. NVentures (Santa Clara), Lifeforce Capital, Madrona Venture Group, Sahsen Ventures, WRF Capital, Altitude Life Science Ventures and Menlo Ventures also participated in the round. The company is a developer of a biotechnology platform designed for creating a novel class of medicines to precisely target disease biology.

restor3d: The company raised $70 million of Series A venture funding in a deal led by Summers Value Partners on June 5, 2024. The transaction was supported by $15 million of debt financing. Other undisclosed investors also participated in the round. The company is a developer of 3D-printed implant technology.

Interius: The company raised $51.4 million in Series B venture funding from undisclosed investors on June 3, 2024, putting the company’s pre-money valuation at $80 million. The company is a developer of a gene delivery platform designed to treat hematologic malignancies and other cancers.

Osteal Therapeutics: The company raised $50 million of Series D venture funding in a deal led by Zimmer Biomet Holdings on June 5, 2024, putting the company’s pre-money valuation at $215 million. Johnson & Johnson Innovation – JJDC, HM Capital, Gideon Strategic Partners and other undisclosed investors also participated in the round. The company is a developer of infection therapeutics designed to significantly reduce the mortality, morbidity, and cost of care associated with musculoskeletal infections.

Eko: The company raised $40 million of Series D venture funding in a deal led by ARTIS Ventures, NTTVC and Highland Capital Partners on June 5, 2024, putting the company’s pre-money valuation at $238 million. LG Technology Ventures, What If Ventures, and Double Point Ventures also participated in the round. The company is a developer of an artificial intelligence-powered digital stethoscope designed to aid heart and lung disease detection.

Iambic Therapeutics: The company raised $38.4 million of Series B2 venture funding from undisclosed investors on June 4, 2024. The company is a developer of a therapeutic discovery quantum molecular simulation engine.

Envisagenics: The company raised $25 million in Series B venture funding from Third Kind Venture Capital, Empire State Development, Red Cell Partners and Bristol Myers Squibb on June 4, 2024, putting the company’s pre-money valuation at $125 million. The company is a developer of a bioinformatics platform intended to accelerate the development of novel therapeutics.

IconOVir Bio: The company raised $20.2 million of venture funding from Wellington Management and other undisclosed investors on June 4, 2024 in the form of convertible debt. The company is an operator of a preclinical-stage biotechnology company intended to pioneer the next generation of oncolytic virus therapy to improve the treatment of patients with cancer.

Canary Speech: The company raised $13 million of venture funding from undisclosed investors on June 4, 2024. The company is a developer of a speech recognition technology designed to detect neurological and cognitive diseases.

HyperSpectral: The company raised $8.5 million of Series A venture funding in a deal led by RRE Ventures and Kibo Ventures Partners on June 5, 2024. GC&H Investments and Correlation Ventures also participated in the round. The company is a developer of an AI powered, hardware-agnostic spectral intelligence system that enables real-time identification of pathogens and contaminants.

Acorn: The company raised CAD 11 million of Series A venture funding in a deal led by Merz Aesthetics on June 3, 2024. TELUS Ventures, LabTech Investments, The Leslie Group, Lee Li Holdings and other undisclosed investors also participated in the round. The company is an operator of a regenerative medicine company intended to offer non-invasive cell freezing for future medicinal applications.

Myrtelle: The company raised $6 million of venture funding in the form of convertible debt from undisclosed investors on June 7, 2024. The company is an operator of a gene therapy company intended to offer innovative clinical trials for the treatment of the rare monogenetic disorder.

Purinomia: The company raised $5.3 million of venture funding in the form of convertible debt from undisclosed investors on June 7, 2024. The company is an operator of a biotechnology business intended to treat cancer, autoimmunity, inflammatory disease, and metabolic syndrome.

AcuamarkDx: The company raised $4.94 million of Series A2 venture funding from undisclosed investors on June 4, 2024, putting the company’s pre-money valuation at $80 million. The company is a developer of a cancer screening blood technology designed to detect cancer markers at early stages.

NexEos Bio: The company raised $4.9 million of venture funding from undisclosed investors on June 6, 2024. The company is a developer of medical diagnostics and therapeutics designed to treat eosinophil-related inflammatory diseases.

SciTech Development: The company raised $32 million of venture funding in a deal led by Storm Lake Capital and Pointe Angels on June 4, 2024. The company is a clinical stage, specialty pharmaceutical business that has developed a proprietary nanoparticle delivery platform to maximize the bioavailability of water-insoluble therapeutics, while maintaining or improving safety profiles.

Codetta Bio: The company raised $2.26 million of venture funding from undisclosed investors on June 4, 2024. The company is a developer of a multi-omic biomarker measurement tool designed to understand the genetic, environmental, lifestyle and clinical factors that contribute to individual health and wellness.

NeuroX1: The company raised Series C venture funding from undisclosed investors on June 4, 2024. The company is a developer a computational neuroscience and drug discovery engine designed to identify degenerative disorders of the brain.

Elsie Biotechnologies / GSK: The company was acquired by GSK for $50 million on June 6, 2024. The company is an operator of a biotechnology business intended to discover oligonucleotide therapeutics.

MoNo Chem-Pharm Produkte / Rohto Pharmaceutical: The company reached a definitive agreement to be acquired by Rohto Pharmaceutical for EUR 30 million on June 6, 2024. The company is a manufacturer of pharmaceutical liquids based in Vienna, Austria.

Aesculap Biologics / Octane Medical Group: The company was acquired by Octane Medical Group, a subsidiary of Lonza Group, for an undisclosed amount on June 7, 2024. The company is a manufacturer of medical equipment based in Breinigsville, Pennsylvania.

Artelon / Stryker: The company reached a definitive agreement to be acquired by Stryker for an undisclosed amount on June 3, 2024. The company is a developer of tissue-regrowth technology designed for orthopedic soft tissue reconstruction.

Asensus Surgical / KARL STORZ: The company reached a definitive agreement to be acquired by KARL STORZ for approximately $95 million on June 6, 2024. Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy.

Carevive / Health Catalyst: The company was acquired by Health Catalyst for an undisclosed amount on June 7, 2024. The company is a developer of a digital oncology platform designed to improve cancer patient clinical outcomes while lowering costs.

Entrinsic Bioscience / AmiLyfe Bioscience: The company was acquired by AmiLyfe Bioscience for an undisclosed amount on June 4, 2024. The company is a developer of a bio-mapping and electrophysiology platform designed to discover novel biocatalysts with transformational health benefits.

Sunrise Medical / Platinum Equity: The company entered into a definitive agreement to be acquired by Platinum Equity through an LBO on June 5, 2024 for an undisclosed amount. Sunrise Medical is engaged in the development, design, manufacture and distribution of manual and powered wheelchairs, mobility scooters and customized seating and positioning systems.

TETEC / Octane Biotherapeutics: The company, a subsidiary of B. Braun was acquired by Octane Biotherapeutics, a subsidiary of Octane Medical Group, for an undisclosed amount on June 7, 2024. The company is an opearator of a biotechnology business intended to develop innovative products for the treatment of complex damage and diseases in the human musculoskeletal system.